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ABSTRACT 
Objective: The current investigation was pointed at developing and progressively validating novel, simple, responsive and stable RP-HPLC method 
for the measurement of active pharmaceutical ingredients of Favipiravir and Peramivir and their related substances. 
Methods: A simple, selective, validated and well-defined stability that shows gradient RP-HPLC methodology for the quantitative determination of 
Favipiravir and Peramivir. The chromatographic strategy utilized Inertsil ODS column of dimensions 250x4.6 mm, 5 micron, using isocratic elution with 
a mobile phase of acetonitrile and 0.1 percent orthophosphoric acid (70:30). A flow rate of 1 ml/min and a detector wavelength of 260 nm utilizing the 
PDA detector was given in the instrumental settings. Using the impurity-spiked solution, the chromatographic approach was streamlined. 
Results: Validation of the proposed method was carried out according to an international conference on harmonization (ICH) guidelines. LOD and 
LOQ for the two active ingredients and their impurities were established with respect to test concentration. The calibration charts plotted were 
linear with a regression coefficient of R2
Conclusion: The proposed method to be fast, simple, feasible and affordable in RS condition. During stability tests, it can be used for routine 
analysis of production samples and to verify the quality of drug samples during stability studies. 
>0.999, which means the linearity was within the limit. Recovery, specificity, linearity, accuracy, robustness, 
ruggedness was determined as a part of method validation and the results were found to be within the acceptable range.  
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INTRODUCTION 
Peramivir (trade name Rapivab) is an antiviral medication developed 
for the treatment of influenza by BioCryst pharmaceuticals [1]. In 
October 2009, the experimental antiviral drug peramivir was 
confirmed to be “life saving” effective in the intravenous treatment of 8 
extreme cases of swine flu [2]. On October 23, the U. S. An emergency 
use authorization for peramivir was provided bt the Food and Drug 
Administration (FDA), authorizing the use of the drug in intravenous 
form for hospitalized parents only in cases where the other treatment 
options available are inadequate or unavailable [3]. Two new anti-
influenza medications were launched clinically in Japan in 2010. 
Rapiacta (peramivir), which is provided by intravenous drip injection, 
was one of them [4-6]. Peramivir was the first intravenous 
neuraminidase inhibitor (NAI) approved by the US food and drug 
administration (FDA) for the treatment of influenza [7]. Data from 
randomized controlled trails have shown that peramivir is safe and 
well-tolerated in uncomplicated influenza, with similar or superior 
clinical efficacy to those of placebo and oseltamivir [8-10]. Signs of an 
allergic reaction hive, difficult breathing, swelling in face or throat, 
severe skin reactions [11]. Favipiravir, sold under the brand name 
Avigan among others, is an antiviral medication used to treat influenza 
in Japan [12]. It is also being studied to treat a number of other viral 
infections [13]. There is evidence that use of during pregnancy may 
result in harm to the baby [14, 15]. Research in 2014, suggested that 
Favipiravir may have efficacy in humans, it went unaddressed. 
 
 
A    B 
Fig. 1: Structure of (A) Favipiravir and (B) Peramivir 
MATERIALS AND METHODS 
Chemicals 
Acetonitrile, HPLC-grade orthophosphoric acid, water, were 
purchased from Merck India Ltd, Mumbai, India. APIs of Favipiravir, 
Peramivir standards were procured from Glen mark, Mumbai. 
The instrumentation 
Waters alliance liquid chromatography (model 2695) monitored 
with empower 2.0 data handling system and a detector of 
photodiode array (model 2998) was used for this study [16].  
Method optimization 
To optimize the chromatographic conditions, different ratios of 
phosphate buffer and the acetonitrile in the mobile phase with 
isocratic and gradient mode were tested. However, the mobile phase 
composition was modified at each trial to enhance the resolution 
and also to achieve acceptable retention times. Finally, 0.1% OPA 
buffer and acetonitrile with isocractic elution was selected because 
it results in a greater response of active pharmacy ingredient and 
their impurities. During the optimization of the method various 
stationary phases such as C8, C18
There are some HPLC methods [17-19] reported in the literature, 
but these methods are developed only for routine analysis of ESC 
 phenyl and amino, inertsil ODS 
columns were tested. From these trials the peak shapes were 
relatively good with a inertsil ODS column of 250 x 4.6 mm, 5 µ with 
a PDA detector. The mobile phase flow rate has been done at 254 nm 
in order to obtain enough sensitivity. By using above conditions we 
get retention times of Favipiravir and Peramivir were about 3.003 
and 7.271 min with a tailing factor of 1.063 and 1.401. The number 
of theoretical plates for Favipiravir and Peramivir were 
2089456,1889412 which indicate the column’s successful output the 
% RSD for six replicate injections was around 0.94% the proposed 
approach suggests that it is extremely precise. According to ICH 
guidelines, the method established was validated.  
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and FLU in bulk and formulation studies. The developed HPLC 
method was utilized for the estimation of the combined drugs by in 
vitro method. Different extractions were tried using acetonitrile, 
methanol, and dimethylformamide [20]. 
Validation procedure  
The analytical parameters such as system suitability, precision, 
specificity, accuracy, linearity, robustness, LOD, LOQ, forced degradation 
and stability were validated according to ICH Q2 (R1) guidelines [21-29]. 
Preparation of buffer 
1 ml of ortho phosphoric acid is dissolved in 1 lt of HPLC grade 
water and filter through 0.45 µ filter paper.  
Chromatographic conditions 
The HPLC analysis was performed on reverse phase HPLC system 
with isocratic elution mode using a mobile phase of acetonitrile and 
0.1% OPA and Inertsil ODS column (250x4.6 mm, 5 μ) column with a 
flow rate of 1 ml/min. 
Diluent 
Water and Acetonitrile in the ratio (50:50) is used as diluent. 
Preparation of the standard stock solution 
For standard stock solution preparation, add 70 ml of diluents to 
100 mg of Favipiravir and 100 mg of Peramivir taken in a 100 ml 
volumetric flask and sonicate for 10 min to fully dissolve the 
contents and then make up to the mark with diluent. 
Preparation of standard solution 
1 ml of solution is drawn from the above normal stock solution into 
a 10 ml volumetric flask and diluted up to the level. 
Preparation of sample solution 
Take 130 mg of the sample drug Favipiravir and 100 mg of the 
sample drug Peramivir into a 100 ml volumetric flask and add 70 ml 
of diluents and sonicate for 10 min to fully dissolve the contents and 
then make up the mark with diluent. This solution is filtered into a 
device using a 0.45µ nylon syringe in a vial. 
RESULTS AND DISCUSSION 
The main analytical challenge during the development of a new 
method was to separate active Pharma ingredients from their 
impurities. In order to provide a good performance, the 
chromatographic conditions were optimized.  
System suitability 
In System, suitability injecting standard solution and reported USP 
tailing and plate count values are tabulated in table 1. 
Specificity 
In this test method placebo, sample and standard solutions were 
analyzed individually to examine the interference. The below fig. 
shows that the active ingredients were well separated from blank 
and their excipients and there was no interference of placebo with 
the principal peak. Hence the method is specific. 
  
Table 1: Results of system suitability 
System suitability parameter Acceptance criteria Drug name 
Favipiravir  Peramivir  
USP Plate Count NLT 2000  38417  3264 
USP Tailing NMT 2.0 1.07 1.04 
USP Resolution NLT 2.0 - 8.64 
% RSD NMT 2.0 0.71 0.89 
 
 
Fig. 2: Chromatogram of system suitability 
 
 
Fig. 3: Chromatogram of blank 
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Table 2: Linearity of favipiravir and peramivir 
S. No. Conc µg/ml  Favipiravir area count Conc. µg/ml  Peramivir area count 
1 10 208946 10 188941 
2 25 509623 25 460832 
3 50 1044728 50 944706 
4 75 1554351 75 1405538 
5 100 2089456 100 1889419 
6 125 2599079 125 2350244 
7 150 3134184 150 2834118 
Correl coef  0.99998  0.9999 
Slope 20879.909 18880.871 






Fig. 4: Calibration plots of (A) Favipiravir (B) Peramivir 
 
Linearity 
The area of the linearity peak versus different concentrations has been 
evaluated for Favipiravir, Peramivir, as 10,25,50,75,100,125,150 
percent respectively. Linearity was performed in the range of 10-
150µg/ml of Favipiravir and 10-150µg/ml of Peramivir. The 
correlation coefficients achieved greater than 0.999 for all. 
Accuracy 
In this method, Accuracy was conducted in triplicate by analyzing 
active pharma ingredient sample solution spiked with known 
amounts of all the impurities at three kinds of concentration levels 
of 50, 100 and 150% of each at a specified limit. For all impurities, 
percentage recoveries were measured and found to be within the 
limit. The accuracy and reliability of the developed method were 
established. The percentage recovery values were found to be in the 
range of 100.154-100.624% for Favipiravir and 99.512-99.918% for 
Peramivir. The results are given in table 3, 4 and 5. 
Precision 
In method precision study prepare six different samples in the 
concentration of Favipiravir (100 ppm) and Peramivir (100 ppm) 
are injected into HPLC system. Favipiravir %assay found to be in the 
range of 100.136-100.561 and Peramivir %assay found to be in 
range of 100.261-100.517. These results are given below table 4. 
  
Table 3: Results of accuracy 
S. No. % Level Favipiravir % recovery Peramivir % recovery 
1 50 100.154 99.512 
2 100 100.624 99.861 
3 150 100.417 99.981 
mean  100.534 99.78467 
SD  0.106108 0.24364 
 Mean+SD (n=3) 
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Table 4: Intraday precision results of favipiravir and peramivir 
Favipiravir Peramivir 
S. No. Conc.(µg/ml) Area counts % assay as is Conc.(µg/ml) Area counts % assay as is 
1  
100 
2089456 100.561  
100 
1889419 100.264 
2 2089451 100.478 1889426 100.517 
3 2089444 100.362 1889435 100.284 
4 2089441 100.287 1889441 100.361 
5 2089420 100.514 1889422 100.485 
6 2089450 100.136 1889434 100.234 
% RSD 1.06 0.918 
mean 100.3897  100.3575 




Fig. 5: Chromatogram of sample 
 
Intermediate precision 
Six replicates of the sample solution were studied by various 
researchers, and on separate days different instruments were tested. 
The peak regions used to determine mean percent RSD values have 
been calculated. The results are given in the following table. 
Intraday precision 
Six replicates of a sample solution containing Favipiravir 
(100μg/ml) and Peramivir (100μg/ml) were analysed on the same 
day. Peak areas were calculated, which were used to calculate mean, 
SD and %RSD values.  
Interday precision 
Six replicates of a sample solution containing Favipiravir 
(100μg/ml) and Peramivir (100μg/ml) were analysed on a different 
day. Peak areas were calculated which were used to calculate mean, 
SD and %RSD values. The present method was found to be precise as 
the RSD values were less than 2% and also the percentage assay 
values were close to be 100%. The results are given in table 5 [16]. 
 
Table 5: Inter-day outcomes of accuracy of favipiravir and peramivir 
Favipiravir Peramivir 
S. No. Conc.(µg/ml) Area counts % assay as is Conc.(µg/ml) Area count % assay as is 
1  
100 
2089451 100.241  
100 
1889414 100.482 
2 2089461 100.054 1889406 100.612 
3 2089312 100.354 1889396 100.536 
4 2089366 100.687 1889354 100.417 
5 2089414 100.471 1889341 100.532 
6 2089457 100.289 1889411 100.417 
%RSD 0.89 1.04 
Mean 2089410 100.4993 
SD 60.078 0.07611 
Mean+SD (n=6) 
 
LOD and LOQ 
The LOD concentrations for Favipiravir are 1.818 µg/ml and s/n 
values is 8 and Peramivir 1.818 µg/ml and s/n value 6. The LOQ 
concentration for Favipiravir 6.248 µg/ml and their s/n values are 
23 and Peramivir their 6.248 µg/ml and s/n value is 28. The method 
is validated as per the US FDA guidelines [30]. 
Robustness 
The conditions of the experiment were designed to test the 
robustness of the established system intentionally altered, such as 
flow rate, mobile phase in organic percentage in all these varied 
conditions. Robustness results for favipiravir and peramivir found to 
be within the limit and results are tabulated in table 7. 
 
Table 6: LOD and LOQ for favipiravir and peramivir 
Favipiravir Peramivir 
LOD  LOQ LOD LOQ 
Concentration s/n Concentration s/n concentration s/n Concentration s/n 
1.818µg/ml 8 6.248µg/ml 23 1.818µg/ml 6 6.248µg/ml 28 
Lingabathula et al. 







Fig. 6: Chromatogram of (A) LOD and (B) LOQ 
 
Table 7: Robustness data of favipiravir and peramivir 
Parameter name % RSD 
Favipiravir  Peramivir  
Flow minus (0.8 ml/min 0.62 0.70 
Flow plus (1.2 ml/min) 0.34 0.66 
Organic minus (-10%) 0.56 0.26 
Organic plus (+10%) 0.51 0.61 
 
Stability 
The standard and sample solution was kept at room temperature 
and at 2-8 °C up to 24 h. Then these solutions were pumped into 
the device and calculate the % of deviation from initial to 24 h 
[31]. There was no significant deviation observed and confirmed 
that the solutions were stable up to 24 h percentage of the assay 
was not quite 2%. There is no effect in storage conditions for 
Favipiravir and Peramivir drugs. The results are given below table 
8. 
 
Table 8: Stability results of favipiravir and peramivir 
Stability Favipiravir Peramivir  
Purity % of deviation Purity % of deviation 
Initial 99.86 0.14 99.91 0.09 
6 H 99.74 0.12 99.84 0.07 
12 H 99.62 0.24 99.73 0.18 
18 H 99.51 0.35 99.61 0.30 
24 H 99.46 0.40 99.54 0.37 
 
Degradation studies 
The Peramivir and Favipiravir sample was subjected into various 
forced degradation conditions to effect partial degradation of the 
drug. Studies of forced degradation have been carried out to find out 
that the method is suitable for products of degradation. In addition, 
the studies provide details about the conditions during which the 
drug is unstable, in order that the measures are often taken during 
formulation to avoid potential instabilities. 
Acid degradation 
In acid degradation was done at 1N HCl and degradation was formed 
12.7% for Favipiravir and 13.5% for Peramivir. 
Alkali degradation 
In alkali degradation was done at 1N NaOH and degradation was 
formed 13.7% for Favipiravir and 14.7% for Peramivir. 
Peroxide degradation 
In peroxide degradation was peroformed at 20% hydrogen peroxide 
at 15.14% Favipiravir at 15.14% and 15.15% for Peramivir. 
Reduction degradation 
In reduction degradation, they formed 13.5% Favipiravir and 
Peramivir. 
Lingabathula et al. 
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Table 9: Forced degradation results of favipiravir and peramivir 
Degradation condition Favipiravir Peramivir 
% Assay % Deg % Assay % Deg 
Acid degradation 87.246 12.754 86.421 13.579 
Alkali degradation 86.271 13.729 85.284 14.716 
Peroxide degradation 84.854 15.146 84.841 15.159 
Reduction degradation 86.412 13.588 86.472 13.528 
Thermal degradation 99.231 0.769 99.547 0.453 
Hydrolysis degradation 99.457 0.543 99.145 0.855 
 
Thermal degradation 
In thermal degradation the sample was degradated 0.76% for 
Favipiravir and 0.45% for Peramivir. 
Degradation of hydrolysis 
In hydrolysis degradation the sample was degradated 0.54% for 
Favipiravir and 0.85% for Permaivir. 
All degradation results are tabulated in table 9. 
CONCLUSION 
We present in this article simple, selective, validated and well-
defined stability that shows gradient RP-HPLC methodology for the 
quantitative determination of Favipiravir and Peramivir. All the 
products of degradation formed during the stress conditions and the 
related active pharma ingredients are well separated and peaks 
were well resolved from each other and separate with an 
appropriate retention time indicating that the proposed method to 
be fast, simple, feasible and affordable in RS condition. Therefore the 
developed method during stability tests, it can be used for routine 
analysis of production samples and to verify the quality of drug 
samples during stability studies. 
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